Development of vaccine against concurent African swine fever infections that promote eclipse of it’s spread in Ukraine

Abstract

Research results and discussion. All vaccinated adult mouse (n=12) at contrast to unvaccinated (n=8) were alive after its inoculation with broth culture of Mannheimia haemolytica in dose 0.5 cm 3 (10 5 BC 50) during 1 month of trials. Level of vaccinated mouse seroconversion on PRRS, PCV-2 and bacterial antigens was 0; 1/2.30+0.11 and 1/351.00+5.73 (P<0.01), in correspondence. All vaccinated pigs (n=5) after first injection had a levels of seroconversion on PRRS, PCV-2 and bacterial antigens (3 week after vaccination) 1/8.80+2.05; 1/22.50+7.73 and 1/51.00+6.88 (P<0.05), in correspondence. After revaccination (3 week after first injection) pigs had a levels of seroconversion on PRRS, PCV-2 and bacterial antigens (3 week after second injection) 1/17.40+0.78; 1/34.23+0.73 and 1/121.11+2.44 (P<0.05), in correspondence. Conclusions. Modified vaccine "ReproSuiVac-IECVM" are ready to clinical trials against the concurrent ASF-hemolytic pasteurellosis infections that promote of blind spreading of ASF agent in the quarantine areas of ASF outbreaks (promote of its attribution) in Ukraine.